These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 10884587)

  • 1. Synergistic anti-tumor activity of a novel immunomodulator, BCH-1393, in combination with cyclophosphamide.
    Kadhim S; Penney C; Lagraoui M; Heibein J; Attardo G; Zacharie B; Connolly T; Gagnon L
    Int J Immunopharmacol; 2000 Sep; 22(9):659-71. PubMed ID: 10884587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity.
    Saxton ML; Longo DL; Wetzel HE; Tribble H; Alvord WG; Kwak LW; Leonard AS; Ullmann CD; Curti BD; Ochoa AC
    Blood; 1997 Apr; 89(7):2529-36. PubMed ID: 9116299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and activity of 6-substituted purine linker amino acid immunostimulants.
    Zacharie B; Gagnon L; Attardo G; Connolly TP; St-Denis Y; Penney CL
    J Med Chem; 1997 Aug; 40(18):2883-94. PubMed ID: 9288170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenic chemotherapy in two mouse colon cancer models.
    Taniura T; Iida Y; Kotani H; Ishitobi K; Tajima Y; Harada M
    Cancer Sci; 2020 Oct; 111(10):3527-3539. PubMed ID: 32816355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of forphenicinol, a small molecular immunomodifier, in combination with cyclophosphamide on growth of and immunity to syngeneic murine tumors.
    Nitta K; Tanaka T; Takeuchi M
    Cancer Treat Rep; 1985 Mar; 69(3):285-91. PubMed ID: 3978657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer.
    Sabel MS; Su G; Griffith KA; Chang AE
    Breast Cancer Res Treat; 2010 Jul; 122(2):325-36. PubMed ID: 19802695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
    Gold JE; Zachary DT; Osband ME
    Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
    J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and activity of dipeptides, linked to targeting ligands, as specific NK cell enhancers.
    Abbott SD; Gagnon L; Lagraoui M; Kadhim S; Attardo G; Zacharie B; Penney CL
    J Med Chem; 1998 May; 41(11):1909-26. PubMed ID: 9599240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination.
    Teicher BA; Holden SA; Eder JP; Herman TS; Antman KH; Frei E
    Semin Oncol; 1990 Feb; 17(1 Suppl 3):18-32. PubMed ID: 2106164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma.
    Kalland T
    Cancer Res; 1986 Jun; 46(6):3018-22. PubMed ID: 3486041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists.
    Manrique SZ; Dominguez AL; Mirza N; Spencer CD; Bradley JM; Finke JH; Lee JJ; Pease LR; Gendler SJ; Cohen PA
    Oncotarget; 2016 Jul; 7(28):42919-42942. PubMed ID: 27341020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with cyclophosphamide supported by various dendritic cell-based vaccines induces diversification in CD4⁺ T cell response against MC38 colon carcinoma.
    Wojas-Turek J; Szczygieł A; Kicielińska J; Rossowska J; Piasecki E; Pajtasz-Piasecka E
    Int J Oncol; 2016 Feb; 48(2):493-505. PubMed ID: 26648160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer.
    Dewan MZ; Vanpouille-Box C; Kawashima N; DiNapoli S; Babb JS; Formenti SC; Adams S; Demaria S
    Clin Cancer Res; 2012 Dec; 18(24):6668-78. PubMed ID: 23048078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines.
    Nigam A; Yacavone RF; Zahurak ML; Johns CM; Pardoll DM; Piantadosi S; Levitsky HI; Nelson WG
    Int J Oncol; 1998 Jan; 12(1):161-70. PubMed ID: 9454900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temporary elimination of IL-10 enhanced the effectiveness of cyclophosphamide and BMDC-based therapy by decrease of the suppressor activity of MDSCs and activation of antitumour immune response.
    Rossowska J; Anger N; Kicielińska J; Pajtasz-Piasecka E; Bielawska-Pohl A; Wojas-Turek J; Duś D
    Immunobiology; 2015 Mar; 220(3):389-98. PubMed ID: 25454807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations.
    Evans R; Fuller JA; Christianson G; Krupke DM; Troutt AB
    Cell Immunol; 1997 Jul; 179(1):66-73. PubMed ID: 9259773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bryostatin/ionomycin-activated T cells mediate regression of established tumors.
    Chin CS; Graham LJ; Hamad GG; George KR; Bear HD
    J Surg Res; 2001 Jun; 98(2):108-15. PubMed ID: 11397126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL.
    Vierboom MP; Bos GM; Ooms M; Offringa R; Melief CJ
    Int J Cancer; 2000 Jul; 87(2):253-60. PubMed ID: 10861484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between modulation of natural killer cell activity and antitumor activity of bropirimine when used in combination with various types of chemotherapeutic drugs.
    Li LH; DeKoning TF; Wallace TL
    Cancer Res; 1987 Nov; 47(22):5894-900. PubMed ID: 3664490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.